The Safety and Immune Response to Influenza Vaccination in Pregnant Women

Influenza Clinical Trial

Official title:

The Safety and Immune Response to Influenza Vaccination in Pregnant Women

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01514708
• Other study ID #: FLU11T12P
• Status: Completed
• Phase: Phase 4
• Start date: November 2011
• Est. completion date: August 2012

Study information

• Verified date: December 2012
• Source: Adimmune Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the antibody response to the influenza vaccine (AdimFlu-S), as measured by hemagglutination inhibition (HAI) at 4 weeks post immunization in pregnant women in compliance with the requirements of the current European Union (EU) recommendations for the evaluation of the immunogenicity for a new formulation of a licensed flu vaccine (CPMP/BWP/214/96). Besides, the vaccine safety will also be evaluated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 46
• Est. completion date: August 2012
• Est. primary completion date: June 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Pregnant female aged = 18 years old.

2. Subject is pregnant for at least 3 months, inclusive.

3. Subject is willing and able to adhere to visit schedules and all study requirements.

4. Subject has read and signed the study-specific informed consent.

Exclusion Criteria:

1. Subject with previous complicated pregnancy or preterm delivery, spontaneous or medical abortion;

2. Subject with history or concurrent high risk of dangerous gestation such as gestational diabetes mellitus (GDM), pregnant induced hypertension, or preeclampsia;

3. Subject received any influenza vaccine within the previous 6 months;

4. Subject has a history of hypersensitivity to eggs or egg protein or similar pharmacological effects to study vaccine;

5. Subject or her family has the history of Guillain-Barré Syndrome;

6. Subject has current upper respiratory illness (URI), including the common cold or nasal congestion within 72 hours;

7. Subject with influenza-like illness as defined by the presence of fever (temperature over 38ºC) and at least two of the following four symptoms: headache, muscle/joint aches and pains (e.g. myalgia/arthralgia), sore throat and cough;

8. Subject receive any treatment with an investigational drug or device, or participation in a clinical study, within 3 months before consent;

9. Subject has immunodeficiency or is under immunosuppressive treatment.

10. Subject received any vaccine within 1 week prior to study vaccination or expected to receive one within 1 week after study vaccination;

11. Subject received any blood products, including immunoglobulin, in the past 3 months before consent;

12. Subject has underlying condition in the investigators' opinion may interfere with evaluation of the vaccine;

Related Conditions & MeSH terms

• Influenza
• Influenza, Human

Intervention

Biological:
• AdimFlu-S Influenza Vaccine
Suspension for injection

Locations

Country	Name	City	State
Taiwan	National Taiwan University Hospital	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
Adimmune Corporation

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary endpoint will be the seroprotection rate which is defined as the proportion of subjects with HAI titer = 1:40. The other immunogenicity endpoints include seroconversion rate and geometric mean folds increase in HAI titer.	The primary endpoint will be the seroprotection rate which is defined as the proportion of subjects with HAI titer = 1:40. The other immunogenicity endpoints include seroconversion rate and geometric mean folds increase in HAI titer. Immunogenicity profile will be assessed before vaccination, 4 weeks after the vaccination and at the end of gestation period.	Immunogenicity profile was assessed before vaccination, 4 weeks after the vaccination and at the end of gestation period. Moreover, the HAI titer of the cord blood was also measured and compared with the maternal blood sample.
Secondary	The secondary endpoint is to evaluate the safety and tolerability profiles including the presence or absence of the pre-specified reactogenicity events and other serious/non-serious adverse events of the AdimFlu-S.	Safety outcomes include immediate reactions at the time of vaccination, solicited local and systemic reactions for 7 days, unsolicited adverse events until the first post-vaccination serum collected (Day 28), and serious adverse events and adverse events of special interest until 8 weeks after the delivery.	The safety information is collected from the day of vaccination to 8 weeks after the delivery.